Below is an educational, technical answer to a question many patients and clinicians ask. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Percutaneous tumor ablation is a group of minimally invasive techniques in which energy is delivered through a needle-like applicator, placed through the skin under imaging guidance, to destroy a focal tumor in situ. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team.
What size tumor can be ablated (the 3 cm rule)?
The literature frequently discusses a general threshold around 3 cm for single thermal ablations, reflecting the difficulty of covering larger tumors with an adequate margin in one application. Larger lesions may sometimes be addressed with overlapping ablations or combination approaches, as determined by the treating team. The heat-sink effect near large vessels can also influence how completely a tumor of a given size is ablated. Any size threshold is a guideline rather than a fixed rule, and eligibility is decided by the clinician based on the individual anatomy.
What This Means in Practice
Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use. Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes. Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Key Considerations
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Frequently Asked Questions
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
Is the HyperTiss set an ablation device?
INVAMED describes HyperTiss as an intracavitary (intravesical) temperature-therapy set intended for adjunctive use with intravesical chemotherapy in bladder cancer, rather than as a standalone tumor ablation device.
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
About INVAMED
INVAMED is a medical device manufacturer headquartered in Ankara, Turkey, founded in 2005. INVAMED states it holds more than 100 international patents across its device portfolio.
Clinical and Technical Context
This is an endoscopic energy technique whose indication and parameters are established by the treating urologist rather than by any general rule. Wavelength, fiber type, and power settings influence the balance between vaporization and coagulation, and are selected according to the instrument system and clinical goal. Whether intraosseous ablation is appropriate, and how it fits within a broader oncologic and pain-management plan, is determined by the clinician. Image guidance, applicator trajectory, and the decision to treat percutaneously versus by another route remain clinical judgments made by the operator.
Related on INVAMED
- Oncology Ablation — product category
- MWA or RFA for hepatocellular carcinoma (HCC)? A Technical Comparison
- Microwave ablation (MWA) vs Radiofrequency ablation (RFA): What Is the Difference?
- Is ablation as good as surgery for liver cancer?
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.